Index

Abciximab in Emergency Stroke Treatment Trial-II (AbESTT-II), 246
abuse liability, 13
actigraphy, 299, 303
active arm comparator designs, 265
active controls, 13, 143, 201–202
active-control trials, 135
acute ischemic stroke, 242
Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN) study, 247
acute stroke treatment, 243
recruitment, 252
acute stroke trials
consent, 251
eyearly and middle development studies, 247
endpoint measures, 245
recruitment, 252
subject recruitment, 251
surrogate consent, 251
ADAGIO trial, 116–117, 122
adaptive design, 91, 93, 97, 98, 247
assessment, 92
definition, 91
neurological trials, 96
sample size re-estimation design, 95
sample size re-estimation methods, 95
adaptive design type, 92, 98
Adaptive Designs Working Group (ADWG), 91
adaptive dose-finding study, 97
adaptive randomization, 94, 251
adaptive seamless design, 95–97
adaptive trials, 13
ADAS-Cog, 101
scale, 230
score, 32, 230
adverse drug event manufacturer responsibility, 161
physician reporting survey, 162
adverse drug event factors, 160–161
adverse drug event reporting, 163, 164
statins, 162
Adverse Event Reporting System (AERS), 163
aggregate spend, 353
Albumin in Acute Stroke (ALIAS) trial, 247
ALS, 273
biomarker, 278
disease models, 273
futility design studies, 279
lead-in design, 279
motor neuron death, 273
mouse model, 273–274
phenotypic heterogeneity, 275
selection designs, 279
symptomatic management, 274
symptomatic treatment, 282
therapies, 273
ALS clinical trials, 273, 275, 279
dosage, 280
dropout rate, 281
drug interactions, 280
eligibility criteria, 275, 281
enrollment, 281
missing data, 278
random effects model, 278
sample size, 280
ALS trial outcome measure, 275
ALS trials
statistical techniques, 278
ALS trials outcome measure longitudinal outcomes, 278
MUNE, 276
muscle strength, 276
survival, 276
vital capacity, 276
ALSFRS-R, 276, 278
ALSSQOL, 278
alternate dosing formulations, 15
alternative hypothesis, 60
alternative hypothesis of superiority, 137
Alzheimer's disease, 11, 14, 19, 25, 29, 113, 132, 203, 204, 227
behavioral outcomes, 233
biological signatures, 228
classification characteristics, 229
diagnosis, 229
diagnostic criteria, 238
disease-modifying therapies, 238
molecular changes, 228
pathology, 227–228
prevention, 236
progression, 233
treatment, 229
Alzheimer's disease Assessment Scale, 103
Alzheimer's disease Cooperative Study-Activities of Daily Living (ADCS-ADL), 252
Alzheimer's disease modification randomized withdrawal design, 236
staggered start design, 236
trial duration, 238
Alzheimer's disease trials, 227, 230, 233, 239
drug safety, 235
efficacy, 236
enrollment issues, 237
minority recruitment, 237
phase I clinical trials, 234–235
phase II clinical trials, 235
phase IIa trials, 235
phase IIb trials, 235
phase III trials, 235
placebo group decline, 237–238
safety measures, 237
study partner, 237
amyloid imaging, 75
Amyotrophic lateral sclerosis (ALS), 243
animal CNS disease models, 21
animal model, 21–22
antegrade reperfusion, 243
antiepileptic drugs (AEDs), 202
antiepileptic drug development, 291
antiepileptic drug safety, 291
antiepileptic drugs, 284
mechanism, 285
antiepileptic drugs trials children, 291
Anti-Kickback Statute, 356
violation, 357
Antiplatelet Trialist Collaboration (APTC) endpoint, 170
any one purpose doctrine, 356
aplastic anemia, 164
Appel rating scale, 278
Arrhythmia Suppression Trial (CAST), 130
as treated analysis, 66
aspirin, 6
<table>
<thead>
<tr>
<th>Page</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>177</td>
<td>clinical trial team, 309</td>
</tr>
<tr>
<td>177</td>
<td>communication, 312</td>
</tr>
<tr>
<td>177</td>
<td>clinical trials, 1, 2, 5, 9, 29</td>
</tr>
<tr>
<td>177</td>
<td>candidates, 177</td>
</tr>
<tr>
<td>177</td>
<td>caregiver participation, 182</td>
</tr>
<tr>
<td>177</td>
<td>censoring, 36</td>
</tr>
<tr>
<td>177</td>
<td>central laboratories, 315</td>
</tr>
<tr>
<td>177</td>
<td>cognitively impaired subjects, 192</td>
</tr>
<tr>
<td>177</td>
<td>committees, 148</td>
</tr>
<tr>
<td>183</td>
<td>critical public engagement, 183</td>
</tr>
<tr>
<td>183</td>
<td>data management services, 314</td>
</tr>
<tr>
<td>147</td>
<td>data review, 147</td>
</tr>
<tr>
<td>147</td>
<td>design, 15, 28</td>
</tr>
<tr>
<td>147</td>
<td>design protocol, 28</td>
</tr>
<tr>
<td>149</td>
<td>drug safety hypothesis, 169</td>
</tr>
<tr>
<td>149</td>
<td>eligibility criteria, 182</td>
</tr>
<tr>
<td>177</td>
<td>endpoint, 244</td>
</tr>
<tr>
<td>177</td>
<td>enforcement, 352</td>
</tr>
<tr>
<td>177</td>
<td>implementation, 338</td>
</tr>
<tr>
<td>177</td>
<td>interpretation of results, 201</td>
</tr>
<tr>
<td>177</td>
<td>intervention risks, 177</td>
</tr>
<tr>
<td>177</td>
<td>investigational agent access, 182</td>
</tr>
<tr>
<td>177</td>
<td>management, 312</td>
</tr>
<tr>
<td>177</td>
<td>participation, 189</td>
</tr>
<tr>
<td>177</td>
<td>patient exclusion, 182</td>
</tr>
<tr>
<td>177</td>
<td>payment, 353</td>
</tr>
<tr>
<td>177</td>
<td>planning, 319, 327</td>
</tr>
<tr>
<td>177</td>
<td>planning process, 309</td>
</tr>
<tr>
<td>177</td>
<td>prospective registration, 176</td>
</tr>
<tr>
<td>177</td>
<td>publication bias, 348</td>
</tr>
<tr>
<td>177</td>
<td>quality assurance system, 344</td>
</tr>
<tr>
<td>177</td>
<td>recruitment, 341</td>
</tr>
<tr>
<td>177</td>
<td>registries, 348</td>
</tr>
<tr>
<td>177</td>
<td>regulatory requirements, 327</td>
</tr>
<tr>
<td>177</td>
<td>reporting, 346</td>
</tr>
<tr>
<td>177</td>
<td>reporting and transparency, 353</td>
</tr>
<tr>
<td>177</td>
<td>results dissemination, 346</td>
</tr>
<tr>
<td>177</td>
<td>results publication, 347</td>
</tr>
<tr>
<td>177</td>
<td>retention, 342–343</td>
</tr>
<tr>
<td>177</td>
<td>safety, 9</td>
</tr>
<tr>
<td>177</td>
<td>set-up phase, 320</td>
</tr>
<tr>
<td>177</td>
<td>site audits, 344</td>
</tr>
<tr>
<td>177</td>
<td>site monitoring, 339–340</td>
</tr>
<tr>
<td>177</td>
<td>site qualification, 339</td>
</tr>
<tr>
<td>177</td>
<td>site selection process, 39</td>
</tr>
<tr>
<td>177</td>
<td>site training, 340</td>
</tr>
<tr>
<td>177</td>
<td>subject payment, 343</td>
</tr>
<tr>
<td>177</td>
<td>timelines, 319</td>
</tr>
<tr>
<td>177</td>
<td>vendors, 316</td>
</tr>
<tr>
<td>259</td>
<td>clinically isolated syndrome (CIS)</td>
</tr>
<tr>
<td>101</td>
<td>cluster headaches</td>
</tr>
<tr>
<td>23</td>
<td>CNS drug delivery</td>
</tr>
<tr>
<td>21</td>
<td>CNS targets</td>
</tr>
<tr>
<td>173</td>
<td>CNS trial challenges</td>
</tr>
<tr>
<td>177</td>
<td>aggressive interventions</td>
</tr>
<tr>
<td>183</td>
<td>ethical research</td>
</tr>
<tr>
<td>183</td>
<td>risks</td>
</tr>
<tr>
<td>177</td>
<td>trial enrollment</td>
</tr>
</tbody>
</table>

asymptomatic intracranial hemorrhage (ICH), 244
atuliren, 25
atrial fibrillation, 6
Avonex Combination Trial, 265
Aβ imaging, 25
Aβ plaques, 227
Barthel Index, 245
baseline severity, 249
baselines, 108
basic exposure requirements, 14
Belmont Report, 174, 183
BEYOND Trial, 265
Best Pharmaceuticals for Children Act (BPCA), 199
beta-amyloid (Aβ1–42), 74
BEYOND Trial, 265
bias, 42
binary outcomes, 107
biochemical biomarkers, 74
bio-creep, 143
bioequivalence, 136
biological therapies, 5
biomarker adaptive designs, 95
biomarkers, 20, 23, 71, 73–74, 127, 243
pharmacodynamic markers, 20
type 0 biomarker, 23
type 1 biomarker, 23
type 2 biomarker, 24
Biomarkers Definitions Working Group
conceptual model, 71
blinding, 43, 45, 136
blood brain barrier, 22, 23
blood-CSF barrier, 24
Bonferroni method, 40
botulinum toxin, 5
brain atrophy, 268
brain imaging, 180
incidental findings, 180
studies, 11
brain intervention study risk, 176
C-11 labeled donepezil, 11
calcitonin gene-related peptide (CGRP) receptor, 96
calcitonin gene-related peptide (CGRP), 97
cancer futility designs, 220
cancer therapy, 275
Cardiac Arrhythmia Suppression Trial (CAST), 71, 130
carotid endarterectomy, 6
carrier-mediated and receptor-mediated transport, 23
carryover, 104
case series, 163
CDP, 47
celecoxib, 170
censored data, 107
Center for Devices and Radiological Health (CDRH), 206
central laboratories, 315
central laboratory criteria, 315
cephalalgia, 11
cerebral infarction, 242
cerebrovascular disease, 1
cGMP regulations, 321
characteristics of instruments, 76
child epilepsy, 291
China, 1
clopidogrel, 266
clinical data management, 207, 209
clinical design, 208
clinical II medical devices, 208
clinical III medical devices, 209
clinical trials scope of work (SOW), 312
clinical care, 174
clinical data management, 326
Clinical Dementia Rating Scale (CDR), 232–233
clinical development, 8, 13, 15, 17
early stage, 9
late stage, 13–15
middle stage, 11, 13
clinical drug safety trials, 170
clinical endpoint
late phase acute stroke study, 246
clinical enrollment duration, 342
clinical equipoise, 175, 176, 178
Clinical Global Impression, 29
clinical guidance documents, 16
Clinical Interview Based Impression of Change (CIBIC), 232
clinical investigators, 182
clinical post-marketing safety assessment, 161
clinical research
competent only policy, 192, 193
clinical research associate (CRA), 311
clinical research consent, 188
clinical research organizations (CROs), 312
Clinical Study Reports (CSR), 347
clinical supplies, 321
clinical supply chain, 321
clinical supply labeling, 323
clinical trial budget, 316, 317
budget management, 319
committees, 318
components, 317
currency fluctuations, 317
data management costs, 318
IRB/EC costs, 319
monitoring budget, 318
vendors, 318
clinical trial design
entry and exclusion criteria, 30
timeline, 30

© in this web service Cambridge University Press www.cambridge.org
Index

Code of Federal Regulations, 73
cognitive behavioral therapy for insomnia (CBT-I), 296
collateral perfusion, 243
Combination Drug Selection Trial, 85
comorbid insomnia, 295
comparative effectiveness studies, 6
comparative selection trial, 88
complete two-period design, 118
participant allocation, 120
statistical model, 118–119
compliance and quality management, 345
concomitant medications, 10
conditional power, 154–155
confidence interval, 33, 63
confirmatory trials, 93, 98
adaptations, 94
confounding, 179
Consolidated Standard of Reporting Trials (CONSORT), See CONSORT
continual reassessment method, 92
stopping criteria, 93
continuous outcomes, 106
control group, 30–31, 42
controlled clinical trial, 42
Coronary Drug Project (CDP), 47
correlative and marker studies, 180
covariate adaptive randomization, 94
CRFs, 326
CRM. See continual reassessment method
modified approaches, 93
crossover design, 101, 110
2-treatment 2-period design, 101
ABRA design, 103, 107
matched crossover design, 109
parallel design, 103
crossover insomnia trials, 301
crossover trials, 101
applications, 101
baselines, 109
logistical challenges, 111
sample size, 101
sequence effects, 104
two-stage approach, 108
with carryover, 105
without carryover, 105
CSF measurement, 326

DATATOP study, 114
DATATOP trial, 115, 121
decision-making capacity, 190–191
Declaration of Helsinki, 174–176, 181, 183
deep brain stimulation (DBS), 218
deep brain stimulation devices, 210
demonstration of effectiveness, 197
Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) trial, 114
device classifications, 322
Disability Assessment for Dementia (DAD) scale, 232
disease modification, 113
modifying effect, 203
modifying effect study, 203
disease prevention effect study, 204
disease prevention study
surrogate marker, 204
disease progression treatment, 203
disease-modifying effect, 124
DMC, 159
DMC Charter, 149
donepezil, 101, 107
dopamine agonist, 218
dopaminergic medication, 218, 219, 222–223
sleep attacks, 222
dose-response relationship, 11
dose-response study, 96
donor out, 66
drug approval, 197
drug safety, 160
active surveillance systems, 164, 165
case definitions, 167
clinical efficacy trials, 169
clinical trials, 168
clinical trials constraints, 168
drug definition, 167
observational epidemiological study, 165
post-market clinical trials, 168
profile trials, 205
relative risk, 165
study approach, 171
drug safety issue identification, 161
drug safety profile, 160
drug safety program, 160
drug stability testing, 322
drugs, lack of increase, 3
drugs, cost, 1
DSMB, 96, 98
Duchenne muscular dystrophy (DMD), 25
dyskinesias, 218
dystrophin, 25
early exploratory (phase I) trials, 92
early phase studies
candidates, 177
eyear stage clinical trials, 69
eyear trial termination, 154, 345
Early vs. Late L-Dopa in Parkinson Disease (ELLDOPA) trial, 115
ECG vendor criteria, 316
ECG vendors, 316
EDSS, 262, 268
EDSS scale, 262
effect size, 250
efficacy, 11, 150, 154
in vivo model, 9
proof-of-efficacy-trials, 12
therapeutic efficacy, 11
efficacy and safety endpoints, 11
efficacy trials, 168
electronic data capture (eDC) technology, 345
eligibility, 48
eligibility criteria, 249
endovascular mechanical treatments, 248
endpoint, 76, 136
model, 70
endpoint selection, 12
enrichment design, 132
enrichment design trial methods, 127
enrichment design trials, 127
advantages, 128, 130, 133
carryover effects, 132
complete enriched enrollment, 128
generalizability, 131
Kopeck mathematical model, 129
limitations, 130
partial enriched enrollment, 128
planning considerations, 131
recruitment efficiency, 131
responder definition method, 129
sample size, 129
sensitivity, 129
strengths, 129
subject response, 128
epilepsy, 284
photoparoxysmal response, 288
epilepsy clinical designs
monotherapy trial design, 292
epilepsy clinical trials
adverse event frequency, 287
assessment of efficacy, 286
definitive proof of efficacy studies, 289
dose-finding study, 289
drug efficacy, 288
electroencephalogram (EEG), 287
exit criteria, 288
failed trials, 292
outcome measures, 287–288
placebo response rate, 292

© in this web service Cambridge University Press
www.cambridge.org
populations, 285
presurgical inpatient study, 289
quality of life scales, 287
seizure clusters, 287
seizure freedom, 288
sudden unexplained death, 291
trial duration, 292
epilepsy drug delivery, 286
epilepsy drug efficacy studies, 289
epilepsy drug models, 285
epilepsy open label extension study, 290
epilepsy regulatory studies, 289
epilepsy syndromes, 284
epilepsy treatment resistance, 284
Eptworth Sleepiness Scale, 222
equal carryover, 105
equivalence, 135–137, See non-inferiority equivalence trials, 135, See non-inferiority trials
eszopiclone (ESZ), 300
ethical criteria, 187
ethical study design, 175
ethics research
justice, 181
EU clinical trials, 326
European Medicines Agency, 16
evaluable subjects analysis, 65
Expanded Disability Status Scale (EDSS), 21
experimental autoimmune encephalomyelitis (EAE), 257
experimental autoimmune encephalomyelitis (EAE) model limitations, 258
exploratory outcomes, 29
fair market value compensation, 352
false claim billing, 358
False Claims Act, 357–358
violations, 358
family-wise error rate, 150–151
FCPA, 359
FDA, 3
FDA Adverse Event Reporting System, 162
FDA MedWatch program, 161
Federal Anti-Kickback Statute.
See Anti-Kickback Statute
Federal Drug Agency, 5
Federal Food, Drug, and Cosmetic Act
Medical Device Amendments of 1976, 206–207
Federal Regulations 21 Code, 200
fellbamate, 164
financial disclosure regulations, 354
financial disclosure requirement, 354
fingolimod, 266
First Subject First Visit (FSFV), 320
flexible design methods, 152
focal dystonia, 5
Food and Drug Administration Modernization Act (FDAMA), 197
Food, Drug, and Cosmetic Act (the Act), 197
Foreign Corrupt Practices Act.
See FCPA
fully sequential designs, 155
funding mechanisms, 98
funding research (US), 3
futility analysis, 81, 154
futility assessment, 97
futility design, 78, 80–81, 248
criterion of superiority, 79
neuroprotective agents, 78
sample size, 82
single-arm design, 79, 84
two-arm design, 79
futility design hypotheses, 79
futility outcome, 81
sensitivity, 80
specificity, 80
type I error, 80
type II error, 80
futility design pitfalls, 83
historical control data, 84
sample size, 83
G93A SOD1, 273
gadolinium-enhancing lesions, 257
Gaucher’s disease, 5
GCP inspections, 343–344
General Practitioner Research Database, 167
generalized onset seizures, 286
genomics studies, 75
Glasgow Outcome Scale, 59
global outcome measures, 232
global statistics, 246
GMP, 340
Good Clinical Practice (GCP), 159
Good Manufacturing Practice (GMP).
See GMP
group sequential adaptive randomization design, 97
group sequential methods, 151
development, 154
hazard function, 37
hazard ratio, 38
Health Canada, 347
health-related quality-of-life (HR-QOL) scales, 263
hemorrhagic transformation, 244
HESDE, 142
historical controls, 201, 248
historical evidence of sensitivity to drug effects (HESDE).
See HESDE
human drug development, 21
human drug exposures, 22
human medical research, 174
policies, codes and regulations, 174
regulations, 175
welfare of volunteers, 174
human pharmacokinetics, 10
human pharmacology, 10
human research ethics, 173, 175
human research risk, 173
human volunteer studies, 15
Humanitarian Device Exemption (HDE), 210–211
Humanitarian Use Device (HUD), 210
Huntington’s disease, 346
hypotheses, 31
tone-sided alternative hypothesis, 31
null hypothesis, 31
two sided alternative hypothesis, 31
hypothesis of non-inferiority, 144
hypothesis tests, 150
ICH Guideline E3, 141
IDE application, 211
IDE exempt studies, 212
IDE study, 211
IHASt, 53–54
imaging biomarkers, 75
imiglucerase (Cerezyme), 5
IMP formulation, 323
IMP quantities, 323
IMP quantity forecasting, 323
income of countries, 1
infarction, 243
informed consent, 187, 188, 194
capacity assessment, 190
decision-making capacity, 190
emergency exceptions, 253
probability statements, 189
subject understanding, 189
therapeutic motivation, 194
informed consent forms, 188
insomnia, 295
associated conditions, 297
biomarkers, 299
diagnosis criteria, 304
diary data, 302
intervention goals, 297
neural pathways, 296
perpetuating factors, 295
pharmacologic agents, 297
precipitating factors, 295
sleep diaries, 298
treatment efficacy, 302
insomnia clinical trials, 297, 299
blinding, 302
CBT trials, 300
<table>
<thead>
<tr>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>comparative effectiveness trials, 305</td>
</tr>
<tr>
<td>comparative efficacy trial, 301 controls, 304 dual approach, 301 duration of treatment, 304 efficacy, 303 efficacy and safety, 302 frequency of assessments, 304 hypnictic trials, 305 improvement indicators, 302 menopausal women, 297 neurocognitive tests, 302 psychological interventions, 300 questionnaires, 298 recruitment, 303 retention, 304 safety outcomes, 305 sample size, 302 institutional review board (IRB), 188 intention to treat (ITT), 46–47 intent-to-treat (ITT) principle, 136 strategy, 141 Interactive Response Technology (IRT). See IRT interferon β, 259–260 interim analysis, 49, 151, 157, 250 sample size, 158 internal pilot designs, 95 International Committee on Harmonisation Guidelines, 14 International Conference on Harmonization (ICH), 163 intra-class correlation, 103 Intraoperative Hypothermia for Aneurysm Surgery Trial (IHAST) 53 intra-parenchymal delivery, 23 investigational device exemptions (IDE), 211 investigational medicinal products (IMP), 317 Investigational Product (IP). See clinical supplies investigational research plan, 211 IP accountability, reconciliation and destruction, 325 cradle-to-grave tracking, 325 storage, 325 transportation, 325 IRB notifications, 346 IRT, 324 ischemia, 242 ischemia trials, 243 superiority, 250 IRT strategy, 144 IV rt-PA pilot study, 247 Kaplan-Meier curve, 37 large simple trial, 170 ibuprofen safety, 170–171 last observation carried forward (LOCF), 48, 67 Last Subject Last Visit (LSLV), 320 late exploratory (phase II) trials, 93 Latin square design, 110 L-DOPA, 23 Lennox-Gastaut Syndrome, 286, 290 leviteracacetam, 285 Levin-Robbins-Leu (LRL) sequential selection procedures, 86–87 levodopa, 217–218, 222 melanomas, 222 life expectancy, 1 likelihood-based approach, 111 linomide, 266 lipophilic compounds, 23 log-rank test, 38 Long-term disability trials, 221 LRL. See Levin-Robbins-Leu (LRL) sequential selection procedures Mainland-Gart’s approach, 107 manual muscle testing (MMT), 276 marginal approach, 107 masking, 249. See blinding material corporate events, 346 maximum tolerated dose (MTD), 92 Mechanical Embolus Removal in Cerebral Ischemia (MERC1) trials, 248 MedDRA dictionary, 326 medical coding system, 326 medical devices, 206 legally marketed device, 209 premarket approval, 210 regulatory framework, 207 substantial equivalence, 209 Medical Devices Advisory Committee, 213 Medical Devices Dispute Resolution Panel, 213 medical devices premarket notification, 209 metabolomic approaches, 75 microdialysis, 24 middle phase studies, 250 mild cognitive impairment (MCI), 190, 228 minorities enrollment material, 342 missing at random (MAR), 66 missing completely at random (MCAR), 66 missing data, 66 missing data mechanism, 111 missing at random (MAR), 111 missing completely at random (MCAR), 111 not missing at random (NMAR), 111 missing not at random (MNAR), 66 mitoxantrone, 266 mixed carryover effect, 109 mixed effects model, 107 mixed model repeated measures, 123 MMT, 276 model-based development, 11 modified Rankin scale, 245–246 monotonic spending function, 153 mortality, 137 MRI, 76 MRI measure brain atrophy, 263, 264 MS Functional Composite (MSFC), 262 MS trials adaptive designs, 269 MTD. See maximum tolerated dose multi-center trial, 252 multiple ascending dose studies, 10 multiple dose studies, 10 multiple hypothesis testing, 144 multiple imputation, 67, 123 multiple sclerosis (MS), 5, 76, 178, 257 adverse events, 265 anti-inflammatory therapy, 258 disease free, 268 disease-modifying therapy, 258 drug development, 258 early treatment, 260 gray matter pathology, 258 hypotheses, 258 multiple trials, 266 relapse and treatment, 267 severity drift, 266 subtypes, 259 symptom-based therapies, 258 MRI measures, 264 MRI studies, 263 multiple sclerosis trials enrollment, 260 entrance criteria, 260 informative enrollment, 260, 262 MRI outcome measures, 268 recruitment, 266 multiplicity, 151, 158 N of 1 trials, 110 natalizumab, 5, 265 National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 174 National Institutes of Health, 17 National Multiple Sclerosis Society policies, 178</td>
</tr>
</tbody>
</table>
NDLM, 96
NET-PD futility studies, 81, 84
additive two-arm design, 82
control group, 81
placebo parameter, 82
single-arm study, 81
two-arm design, 82
NET-PD network, 78
neuritic plaques, 227
neurofibrillary tangles, 227–228
neuroimaging, 11
neuroinflammation, 258
neurointerventional devices, 206
neurological device market, 206
Neurological Devices Advisory Panel, 213
neurological worsening, 244
neuropathic pain, 19
neuroprotection, 242, 268
Neuropsychiatric Inventory (NPI), 233
Neuropsychological Test Battery (NTB), 231
neuropsychological testing, 263
Neuro-QOL projects, 69
neurostimulation devices, 206
neurotherapeutics, challenges, 5
neurotrophic factor development, 20
New Drug Applications (NDA), 16
NIH Anticonvulsant Screening Program, 285
NIH Biomarkers Definitions Working Group, 71
NIH Toolbox, 69
NINDS rt-PA acute stroke study, 248
NINDS rt-PA trial, 246
no-adverse effect level (NOAEL), 10
non-inferiority, 142, 250
non-inferiority margin, 122, 138, 169
non-inferiority trials, 169–170
assay sensitivity, 142–143
choice of margin, 141–142
patient noncompliance, 141
sample size, 140
non-invasive imaging techniques, 24
non-significant risk device studies, 211
non-validated CNS interventions, 183
no-pharmacologic effect dose (NOPED), 10
normal distribution, 55
novel therapeutic, 19
nuisance parameters, 94, 103–105
null hypothesis, 46, 60
Numeric Pain Rating Scale, 12
Nuremberg Code, 174, 176
observational epidemiological studies, 170
retrospective cohort study, 166
observational epidemiological study, 165
case control studies, 167
cohort study, 165
cohort study design, 166
cohort study restrictions, 166
confounding, 165
prospective cohort studies, 166
restrospective cohort design, 166
observational epidemiologic study designs
case-control studies, 165
cohort studies, 165
observational epidemiologic study case-control study, 168
nested case-control, 167
ocular coherence tomography (OCT), 264
open label dose escalation studies, 247
Open Report, 148
open-label dose-escalation studies, 247
open-label safety extension studies, 15
ordinal outcome scales
dichotomous treatment, 246
ordinal outcomes scales
trichotomous treatment, 246
orphan diseases, 200
orphan drug approval, 200
orphan drug effectiveness, 200
orphan drugs, 5
outcome measures, 69, 76
outcome-adaptive dose-finding design, 97
paradoxical insomnia, 298
parallel group designs, 114
Parkinson's disease, 1, 19, 101, 107,
113–114, 163, 179, 215
causes, 215
comparative effectiveness trials, 222
confirmatory (phase III) clinical trials, 220
disability, 219
early trials, 217
impulse control disorders, 222
long term disability trials, 221–222
medication, 168
motor complications, 218, 219
motor features, 215
neuropathology, 215
non-motor features, 216
off time, 218
phase II clinical trials, 220
pilot trials, 221
suicide, 222
Parkinson's disease modification, 221
clinical trial, 221
patient population, 223
statistical analysis, 221
Parkinson's disease progression, 219–220, 223
clinical trials, 220
monitoring devices, 219
survival endpoint, 219
Parkinson's disease trials, 216, 218
disease progression modification, 219
missing data, 223
outcome measures, 219
partial onset seizures, 286
passive spontaneous reporting system, 162
patient follow-up, 137
patient non-compliance, 141
patient population, 14
patient reported outcome (PRO), 12,
69
patient selection, 11, 249
Pediatric Research Equity Act (PREA), 199
pediatric studies, 199–200
pediatric study safety data, 199
pediatric written requests (PWRs), 200
pediatric written responses, 200
penumbral salvage, 243
per subject fee (PSF), 318
per-protocol analysis, 141, 144
permissive developmental disorder, 101
PET imaging studies, 75
pharmaceutical promotion, 358
Pharmaceutical Research and Manufacturers of America (PhRMA).
PhRMA principles, 355
pharmacodynamic marker, 25
pharmacodynamic modeling, 11
pharmacodynamic studies, 264
pharmacokinetic modelling, 11
pharmacologic agents, 113
pharmacologic properties, 9
phase I trial, 177
phase I trial design objectives, 177
phase I trial risks, 177
phase I clinical trials, 74, 264
approaches, 92
phase II clinical trials, 74, 264
phase III clinical trials, 264
PhRMA adaptive dose ranging studies working group, 93
PhRMA Code, 355
physicians withdrawal checklist, 12
Pittsburgh Imaging agent B (PIB), 11
placebo control trial ethics, 178
placebo controls, 178
principles of justice, 181
placebo group, 202
placebo response rates, 12
placebo responses, 179
placebo-to-match (PTM). See PTM
polysomnography (PSG), 298–299, 303
population, 53, 54
population distribution, 54–56
population parameters, 54
population standard deviation, 57
positron emission tomography (PET), 11, 75
post-market drug safety, 160–161
pre-approval drug safety assessment, 160
PRECISION trial, 170
preclinical experiments, 176
researcher responsibility, 177
pre-IDE process, 212
pre-IDE submission, 213
premarket approval (PMA), 214
primary insomnia, 295
primary outcome, 29
primary progressive multiple sclerosis (PPMS), 257, 260
principal investigator (PI), 311
principle of responsiveness, 181
PROACT I, 243
progressive multifocal leukoencephalopathy (PML), 265
project manager (PM), 309
proteomics, 75
protocol feasibility, 338
PROUD trial, 116, 118
pseudo-placebo withdrawal study, 290
PTM, 322
public Advisory Committee meetings, 16
Public Health Service Act, 197
putative disease related pathways, 21
p-value, 65
QALS trial, 85
quality control monitoring, 46
Quality of Life-AD (QOL-AD), 234
radio-labeled receptor ligands, 24
random effects models, 107
random error, 42, 44, 45, 50
randomization, 65, 136
randomization allocation ratio, 249
randomized clinical trial, 31, 135
randomized controlled stroke trials, 247
randomized controlled therapeutic trials, 147
randomized controlled trial, 136, 178
randomized start trials, 128, 204
randomized withdrawal trials, 204
outcome measure, 202
rapid endpoint, 85
recanalization, 242, 243
recruitment and retention plan, 341
recruitment and retention plans, 342
regression models, 67
regulatory reporting requirements, 347
relative risk. See hazard ratio
remyelination strategies, 258
Request for Proposal (RFP), 312
research ethics, 174
fair research design, 181
justice, 181
principles, 175
research participants, 3
Resource Utilization in Dementia (RUD) scale, 233
response adaptive design, 109
response-adaptive randomization, 94
reverse multiplicity problem, 144
reverse placebo effect, 131
rhabdomyolysis, 166
riluzole, 280
routine trial closure, 341, 345
RRMS trials
placebo-controlled trials, 265
relapse number, 262
rt-PA treatment, 251
safe harbor rules, 357
safety and tolerability issues, 12, 15
safety and tolerability profile, 14
safety endpoints, 69
safety of research participants, 356
safety or tolerability issues, 11
safety pharmacology studies, 9
safety studies, 155
sample mean, 52
sample size, 33, 94, 250
sample size adjustment, 251
sample size re-estimation, 15
statistical analysis plan, 327
schizophrenia, 19
secondary outcomes, 29
secondary progressive MS (SPMS), 257
Securities Exchange Act of 1934, 346
seizure diary, 286–287
seizure prophylaxis, 6
seizures, 284
selection design, 78
selection of endpoints, 76
selection procedures, 84–86
indifference zone approach, 85
sequential selection procedures, 85
sensitivity analyses, 48
sequential monitoring, 94
serious adverse events (SAEs), 161, 244
serotonergic effects, 11
serotonin-norepinephrine reuptake inhibitors, 11
severe impairment battery (SIB), 232
sham control studies, 223
sham surgical approach, 43, 218
sham surgical controls, 179, 223
conditions of use, 179, 180
ethical critique, 179
intervention studies, 179
shift analysis, 246, 247
sICH, 250
significance level, 62, 151
significant risk device, 211
simple carryover, 110
simple random sample, 54
single ascending dose studies, 9
single dose studies, 10
single imputation, 67
single photon emission computerized tomography (SPECT), 75
single treatment arm studies, 248
site coordinator, 312
site manager (SM), 311
Site Monitoring Visit (SMV), 340
sliding dichotomy analysis, 246
SMV, 341
societal benefit, 3
solanezumab, 25
spending functions, 153
SPORTIF III trial, 138, 141–142
standard deviation, 53
standard of care (SOC) costs, 318
state biomarker, 73
statistical software, 155, 157
EAST, 157
ldBounds package, 155
R-project, 155
SAS, 156
SAS, 52–53
step-forward randomization, 252, 252
stopping boundaries, 152, 155, 157
Haybittle-Peto method, 152
O’Brien and Fleming method, 152
Pocock method, 152, 154
stratification factors, 48
stroke prevention trials, 253
Stoke Prevention using Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) III trial. See Sportif III trial
Stroke Therapy Academic Industry Roundtable (STAIR) recommendations, 242
Stoke–Acute Ischemic NXY Treatment II (SAINT II) trial, 246
stroke-specific outcome measures, 245
structural imaging, 76
Student’s t-distribution, 55
study forms, 46
substantial evidence of effectiveness, 197
clinical trials, 200–201
single trial elements, 198
single trials, 198
sufficient washout periods, 107
Sunshine Act, 353
superiority, 250
superiority to placebo, 142
superiority trial, 137
patient noncompliance, 140
sample size, 140
surrogate consent, 191
surrogate endpoint, 71
surrogate markers, 198, 203
clinical outcomes, 198, 199
studies, 198
surrogate outcome measures, 71
symptomatic and disease-modifying effects, 113
symptomatic intracranial hemorrhage (sICH), 244
T2 hyperintense lesions, 263
Tacrine Consortium study, 132
tau, 227
TEMPO trial, 116
test of significance, 32
therapeutic development, 19
therapeutic development programs, 71
therapeutic misconception (TM), 193
time to event trial, 290
tissue plasminogen activator, 97
TNK trial, 251
TOAST (III) trial, 147, 150
data monitoring committee, 149
tolerability profile, 10
tolerable dose range, 10
trait biomarker, 73
treatment approval, 203
treatment by period interaction, 104
trial monitoring, 159
trial termination, 159
Tufts quantitative neuromuscular examination (TQNE), 276
two-arm non-inferiority trial
sample size, 140
two-period design, 114, 221
ADAGIO trial, 120
additional treatment, 121
delayed start design, 116, 118
eligibility criteria, 120
evaluation, 121
limitations, 124–125
missing data, 123
multiple statistical testing, 122
period duration, 120
primary analyses, 121–123
PROUD, 120
sample size, 124
withdrawal design, 115, 116
two-stage adaptive dose-ranging design, 96
type I error, 61, 150, 151
type II error, 61
UK Bribery Act, 359
unblinding, 132
unequal carryover, 106
unexpected adverse drug events, 161
Unified Parkinson's Disease Rating Scale (UPDRS), 216, 219
United States drug safety system, 161
unvalidated surrogate markers, 198
US Physician Payments Sunshine Act (Sunshine Act), 353
variability, 53
variance, 53
virtual biotechnology firms, 5
warfarin, 6
washout periods, 132
Wilcoxon-rank sum test, 106
women and minority participation, 342
ximelagatran, 138, 141
zolpidem, 301
α spending function, 153, 154